Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.

Michel Ducreux,Olivier Bouché,J.P. Pignon,Mireille Mousseau,Jean-Luc Raoul,P. Cassan,B. Leduc,C. Berger,A. Dunant,J. Fournet,Laurent Bedenne

Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.

2006

Michel Ducreux
Olivier Bouché
J.P. Pignon
Mireille Mousseau
Jean-Luc Raoul
P. Cassan
B. Leduc
C. Berger
A. Dunant
J. Fournet
Laurent Bedenne

LV5FU2 with high-dose leucovorin (LV), weekly infusional 5-fluorouracil (5FU) (AIO schedule) and raltitrexed have been demonstrated to be active agents in first-line treatment of colorectal cancer. We

Keywords:

Immunology
Pathology
Clinical trial
Performance status
Cancer
Medicine
Colorectal cancer
Progression-free survival
Raltitrexed
Metastasis
Fluorouracil
Antimetabolite
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations